Edition:
United States

Aurobindo Pharma Ltd (ARBN.NS)

ARBN.NS on National Stock Exchange of India

601.90INR
23 Feb 2018
Change (% chg)

Rs15.05 (+2.56%)
Prev Close
Rs586.85
Open
Rs589.00
Day's High
Rs612.00
Day's Low
Rs588.05
Volume
5,799,249
Avg. Vol
2,350,495
52-wk High
Rs809.45
52-wk Low
Rs503.05

Latest Key Developments (Source: Significant Developments)

Aurobindo Pharma Says Approved Dividend Of 1 Rupee Per Share
Wednesday, 7 Feb 2018 07:13am EST 

Feb 7 (Reuters) - Aurobindo Pharma Ltd ::SAYS APPROVED SECOND INTERIM DIVIDEND OF 1 RUPEE PER SHARE.  Full Article

India's Aurobindo Pharma Dec-Qtr Consol Net Profit Rises About 3 Pct
Wednesday, 7 Feb 2018 07:09am EST 

Feb 7 (Reuters) - Aurobindo Pharma Ltd ::DEC QUARTER CONSOL NET PROFIT 5.95 BILLION RUPEES VERSUS 5.79 BILLION RUPEES LAST YEAR.CONSENSUS FORECAST FOR DEC QUARTER CONSOL NET PROFIT WAS 6.71 BILLION RUPEES.DEC QUARTER CONSOL NET SALES 42.69 BILLION RUPEES VERSUS 38.44 BILLION RUPEES LAST YEAR.  Full Article

Aurobindo Pharma Gets U.S. FDA Approval For Fondaparinux Sodium Injection
Wednesday, 27 Dec 2017 01:35am EST 

Dec 27 (Reuters) - Aurobindo Pharma Ltd ::SAYS GETS U.S. FDA APPROVAL FOR FONDAPARINUX SODIUM INJECTION.  Full Article

Aurobindo Pharma gets U.S. FDA nod for esomeprazole magnesium DR capsules OTC
Tuesday, 17 Oct 2017 01:21am EDT 

Oct 17 (Reuters) - Aurobindo Pharma Ltd :Says ‍received final approval from U.S. FDA to manufacture esomeprazole magnesium delayed-release capsules OTC, 20mg​.Says ‍product will be launched immediately​.  Full Article

India's Aurobindo Pharma June-qtr consol profit down about 11 pct
Wednesday, 9 Aug 2017 08:14am EDT 

Aug 9 (Reuters) - Aurobindo Pharma Ltd ::June quarter consol net profit 5.19 billion rupees versus 5.85 billion rupees last year.Consensus forecast for June quarter consol net profit was 5.67 billion rupees.June quarter consol net sales 36.21 billion rupees versus 37.05 billion rupees last year.  Full Article

Aurobindo Pharma gets USFDA approval for Sevelamer Carbonate tablets
Tuesday, 18 Jul 2017 11:40pm EDT 

July 19 (Reuters) - Aurobindo Pharma Ltd :Says Aurobindo Pharma receives USFDA approval for Sevelamer Carbonate tablets.Says product is being launched immediately.Drug indicated for control of serum phosphorus in patients with chronic kidney disease on dialysis.  Full Article

Aurobindo Pharma gets USFDA approval for drug for treating chronic kidney disease
Thursday, 15 Jun 2017 12:53am EDT 

June 15 (Reuters) - Aurobindo Pharma Ltd :Aurobindo Pharma - receives USFDA approval for Sevelamer Carbonate Oral Suspension.Aurobindo Pharma - product is being launched immediately.Aurobindo Pharma - drug used for treatment of patients with chronic kidney disease.  Full Article

U.S. FDA says approves first generic versions of Strattera
Tuesday, 30 May 2017 04:36pm EDT 

May 30 (Reuters) - Glenmark Pharmaceuticals Ltd :U.S. Food and Drug Administration says approved first generic versions of Strattera for attention-deficit/hyperactivity disorder in pediatric, adult patients‍​.U.S. FDA says Apotex, Teva Pharmaceuticals USA, Aurobindo Pharma, Glenmark Pharmaceuticals gained approval to market Atomoxetine in multiple strengths.  Full Article

Aurobindo Pharma expects U.S. drug price erosion to continue for at least another 4 qtrs - exec
Tuesday, 30 May 2017 12:09am EDT 

May 30 (Reuters) - Aurobindo Pharma Ltd :Exec says expects U.S. drug price erosion to continue for at least another four quarters.Exec says price erosion in U.S. here to stay; only the fittest, with a broad number of drug applications will survive..  Full Article

Aurobindo Pharma says US FDA issued form 483 with 6 observations for unit-III
Wednesday, 19 Apr 2017 05:11am EDT 

April 19 (Reuters) - Aurobindo Pharma Ltd :Clarifies on news item "US FDA issues 5-6 'largely procedural' observations to Aurobindo Pharma's Unit-III".Says have been issued a form 483 with 6 observations.Observations are all on procedural improvements.Says none of observations related to data integrity.  Full Article

BRIEF-Aurobindo Pharma Says Approved Dividend Of 1 Rupee Per Share

* SAYS APPROVED SECOND INTERIM DIVIDEND OF 1 RUPEE PER SHARE Source text for Eikon: Further company coverage: